Skip to main content
SpringerLink
Log in

Nonpituitary Sellar Masses and Infiltrative Disorders

  • Chapter
  • First Online:
Pituitary Disorders of Childhood

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

Supra- and intrasellar tumors constitute 10% of all pediatric CNS tumors and may cause endocrine dysfunction due to their close proximity to the hypothalamic-pituitary axis. Endocrine dysfunction may exist at presentation or can occur after surgical intervention or evolve subsequently during or after completion of chemotherapy or radiotherapy. Apart from pituitary adenomas, which comprise approximately 90% of all sellar tumors, there are tumors or tumor-mimicking lesions of non-pituitary origin occurring in the suprasellar region. These non-pituitary sellar masses can be developmental in origin, inflammatory, immunologic or vascular in nature and are further categorized as benign or malignant. In this chapter, we discuss the clinical and neuroradiologic presentation of non-pituitary supra- and intrasellar tumors that occur in the pediatric population, along with the histologic and molecular characterization of these tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wells EM, Packer RJ. Pediatric brain tumors. Continuum (Minneap Minn). 2015;21(2 Neuro-oncology):373–96.

    Google Scholar 

  2. Ostrom QT, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol. 2015;17(Suppl 4):iv1–iv62.

    PubMed  PubMed Central  Google Scholar 

  3. Ostrom QT, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol. 2017;19(suppl_5):v1–v88.

    PubMed  PubMed Central  Google Scholar 

  4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.

    PubMed  Google Scholar 

  5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.

    PubMed  Google Scholar 

  6. Arora RS, et al. Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England. Neuro-Oncology. 2009;11(4):403–13.

    PubMed  PubMed Central  Google Scholar 

  7. Schroeder JW, Vezina LG. Pediatric sellar and suprasellar lesions. Pediatr Radiol. 2011;41(3):287–98; quiz 404–5.

    PubMed  Google Scholar 

  8. Surawicz TS, et al. Descriptive epidemiology of primary brain and CNS tumors: results from the central brain tumor registry of the United States, 1990–1994. Neuro-Oncology. 1999;1(1):14–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Seeburg DP, Dremmen MH, Huisman TA. Imaging of the sella and parasellar region in the pediatric population. Neuroimaging Clin N Am. 2017;27(1):99–121.

    PubMed  Google Scholar 

  10. Huang BY, Castillo M. Nonadenomatous tumors of the pituitary and sella turcica. Top Magn Reson Imaging. 2005;16(4):289–99.

    PubMed  Google Scholar 

  11. Freda PU, Wardlaw SL, Post KD. Unusual causes of sellar/parasellar masses in a large transsphenoidal surgical series. J Clin Endocrinol Metab. 1996;81(10):3455–9.

    CAS  PubMed  Google Scholar 

  12. Valassi E, et al. Clinical features of nonpituitary sellar lesions in a large surgical series. Clin Endocrinol. 2010;73(6):798–807.

    Google Scholar 

  13. McCrea HJ, et al. Pediatric suprasellar tumors. J Child Neurol. 2016;31(12):1367–76.

    PubMed  Google Scholar 

  14. Wilne S, et al. Presentation of childhood CNS tumours: a systematic review and meta-analysis. Lancet Oncol. 2007;8(8):685–95.

    PubMed  Google Scholar 

  15. Wilne SH, et al. The presenting features of brain tumours: a review of 200 cases. Arch Dis Child. 2006;91(6):502–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Wilne S, et al. Progression from first symptom to diagnosis in childhood brain tumours. Eur J Pediatr. 2012;171(1):87–93.

    PubMed  Google Scholar 

  17. Shin JL, et al. Cystic lesions of the pituitary: clinicopathological features distinguishing craniopharyngioma, Rathke's cleft cyst, and arachnoid cyst. J Clin Endocrinol Metab. 1999;84(11):3972–82.

    CAS  PubMed  Google Scholar 

  18. Nishioka H, et al. Magnetic resonance imaging, clinical manifestations, and management of Rathke's cleft cyst. Clin Endocrinol. 2006;64(2):184–8.

    Google Scholar 

  19. Karavitaki N, et al. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol. 2005;62(4):397–409.

    CAS  Google Scholar 

  20. Gan HW, Bulwer C, Spoudeas H. Pituitary and hypothalamic tumor syndromes in childhood. In: De Groot LJ, et al., editors. Endotext. South Dartmouth, MA: MDText.com, Inc; 2000.

    Google Scholar 

  21. Merchant TE, et al. Craniopharyngioma: the St. Jude Children’s research hospital experience 1984–2001. Int J Radiat Oncol Biol Phys. 2002;53(3):533–42.

    PubMed  Google Scholar 

  22. Muller HL. Childhood craniopharyngioma--current concepts in diagnosis, therapy and follow-up. Nat Rev Endocrinol. 2010;6(11):609–18.

    PubMed  Google Scholar 

  23. Taylor M, et al. Hypothalamic-pituitary lesions in pediatric patients: endocrine symptoms often precede neuro-ophthalmic presenting symptoms. J Pediatr. 2012;161(5):855–63.

    PubMed  Google Scholar 

  24. Rivarola MA, et al. Precocious puberty in children with tumours of the suprasellar and pineal areas: organic central precocious puberty. Acta Paediatr. 2001;90(7):751–6.

    CAS  PubMed  Google Scholar 

  25. Daubenbuchel AM, Muller HL. Neuroendocrine disorders in pediatric craniopharyngioma patients. J Clin Med. 2015;4(3):389–413.

    PubMed  PubMed Central  Google Scholar 

  26. Gan HW, et al. Neuroendocrine morbidity after pediatric optic gliomas: a longitudinal analysis of 166 children over 30 years. J Clin Endocrinol Metab. 2015;100(10):3787–99.

    CAS  PubMed  Google Scholar 

  27. Eguchi K, et al. Pituitary function in patients with Rathke’s cleft cyst: significance of surgical management. Endocr J. 1994;41(5):535–40.

    CAS  PubMed  Google Scholar 

  28. Deopujari CE, et al. Pediatric suprasellar lesions. J Pediatr Neurosci. 2011;6(Suppl 1):S46–55.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Kilday JP, et al. Diabetes insipidus in pediatric germinomas of the suprasellar region: characteristic features and significance of the pituitary bright spot. J Neuro-Oncol. 2015;121(1):167–75.

    Google Scholar 

  30. Jorsal T, Rorth M. Intracranial germ cell tumours. A review with special reference to endocrine manifestations. Acta Oncol. 2012;51(1):3–9.

    CAS  PubMed  Google Scholar 

  31. Nielsen EH, et al. Incidence of craniopharyngioma in Denmark (n = 189) and estimated world incidence of craniopharyngioma in children and adults. J Neuro-Oncol. 2011;104(3):755–63.

    CAS  Google Scholar 

  32. Muller HL. Childhood craniopharyngioma. Pituitary. 2013;16(1):56–67.

    PubMed  Google Scholar 

  33. Muller HL. Craniopharyngioma. Handb Clin Neurol. 2014;124:235–53.

    PubMed  Google Scholar 

  34. Warmuth-Metz M, et al. Differential diagnosis of suprasellar tumors in children. Klin Padiatr. 2004;216(6):323–30.

    CAS  PubMed  Google Scholar 

  35. Muller HL. Craniopharyngioma – a childhood and adult disease with challenging characteristics. Front Endocrinol (Lausanne). 2012;3:80.

    Google Scholar 

  36. Muller HL. Craniopharyngioma. Endocr Rev. 2014;35(3):513–43.

    PubMed  Google Scholar 

  37. Caldarelli M, et al. Long-term results of the surgical treatment of craniopharyngioma: the experience at the policlinico gemelli, Catholic University, Rome. Childs Nerv Syst. 2005;21(8–9):747–57.

    CAS  PubMed  Google Scholar 

  38. Hoffman HJ, et al. Aggressive surgical management of craniopharyngiomas in children. J Neurosurg. 1992;76(1):47–52.

    CAS  PubMed  Google Scholar 

  39. Elliott RE, Wisoff JH. Surgical management of giant pediatric craniopharyngiomas. J Neurosurg Pediatr. 2010;6(5):403–16.

    PubMed  Google Scholar 

  40. Barker FG 2nd, et al. Introduction: craniopharyngioma: current and emerging treatment modalities. Neurosurg Focus. 2016;41(6):E1.

    PubMed  Google Scholar 

  41. Board PDQPTE. Childhood craniopharyngioma treatment (PDQ(R)): health professional version. In:PDQ cancer information summaries. Bethesda, MD: National Cancer Institute (US); 2002.

    Google Scholar 

  42. Czyzyk E, et al. Optic pathway gliomas in children with and without neurofibromatosis 1. J Child Neurol. 2003;18(7):471–8.

    PubMed  Google Scholar 

  43. Louis DN, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.

    PubMed  PubMed Central  Google Scholar 

  44. Rashidi M, et al. Nonmalignant pediatric brain tumors. Curr Neurol Neurosci Rep. 2003;3(3):200–5.

    PubMed  Google Scholar 

  45. Armstrong GT, et al. Survival and long-term health and cognitive outcomes after low-grade glioma. Neuro-Oncology. 2011;13(2):223–34.

    PubMed  Google Scholar 

  46. Robert-Boire V, et al. Clinical presentation and outcome of patients with optic pathway glioma. Pediatr Neurol. 2017;75:55–60.

    PubMed  Google Scholar 

  47. Hersh JH. Health supervision for children with neurofibromatosis. Pediatrics. 2008;121(3):633–42.

    PubMed  Google Scholar 

  48. Gutmann DH, et al. Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology. 2002;59(5):759–61.

    CAS  PubMed  Google Scholar 

  49. Listernick R, et al. Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr. 1995;127(5):718–22.

    CAS  PubMed  Google Scholar 

  50. Singhal S, et al. Neurofibromatosis type 1 and sporadic optic gliomas. Arch Dis Child. 2002;87(1):65–70.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Listernick R, et al. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr. 1994;125(1):63–6.

    CAS  PubMed  Google Scholar 

  52. Hamideh D, et al. Isolated optic nerve glioma in children with and without neurofibromatosis: retrospective characterization and analysis of outcomes. J Child Neurol. 2018;33(6):375–82.

    PubMed  Google Scholar 

  53. Nicolin G, et al. Natural history and outcome of optic pathway gliomas in children. Pediatr Blood Cancer. 2009;53(7):1231–7.

    PubMed  Google Scholar 

  54. Prada CE, et al. The use of magnetic resonance imaging screening for optic pathway gliomas in children with neurofibromatosis type 1. J Pediatr. 2015;167(4):851–856.e1.

    PubMed  Google Scholar 

  55. Allen JC. Initial management of children with hypothalamic and thalamic tumors and the modifying role of neurofibromatosis-1. Pediatr Neurosurg. 2000;32(3):154–62.

    CAS  PubMed  Google Scholar 

  56. Brauner R, et al. Growth and endocrine disorders in optic glioma. Eur J Pediatr. 1990;149(12):825–8.

    CAS  PubMed  Google Scholar 

  57. Astrup J. Natural history and clinical management of optic pathway glioma. Br J Neurosurg. 2003;17(4):327–35.

    CAS  PubMed  Google Scholar 

  58. Listernick R, et al. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol. 2007;61(3):189–98.

    CAS  PubMed  Google Scholar 

  59. Kornreich L, et al. Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatosis. AJNR Am J Neuroradiol. 2001;22(10):1963–9.

    CAS  PubMed  Google Scholar 

  60. Balcer LJ, et al. Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging. Am J Ophthalmol. 2001;131(4):442–5.

    CAS  PubMed  Google Scholar 

  61. Rasool N, Odel JG, Kazim M. Optic pathway glioma of childhood. Curr Opin Ophthalmol. 2017;28(3):289–95.

    PubMed  Google Scholar 

  62. Pruzan NL, et al. Spontaneous regression of a massive sporadic chiasmal optic pathway glioma. J Child Neurol. 2015;30(9):1196–8.

    PubMed  Google Scholar 

  63. Campen CJ, Gutmann DH. Optic pathway gliomas in neurofibromatosis type 1. J Child Neurol. 2018;33(1):73–81.

    PubMed  PubMed Central  Google Scholar 

  64. Wan MJ, et al. Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1. J Neuro-Oncol. 2016;129(1):173–8.

    Google Scholar 

  65. Sani I, Albanese A. Endocrine long-term follow-up of children with neurofibromatosis type 1 and optic pathway glioma. Horm Res Paediatr. 2017;87(3):179–88.

    CAS  PubMed  Google Scholar 

  66. Listernick R, et al. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol. 1997;41(2):143–9.

    CAS  PubMed  Google Scholar 

  67. King A, et al. Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet A. 2003;122a(2):95–9.

    PubMed  Google Scholar 

  68. Trevisson E, et al. Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1. J Neuro-Oncol. 2017;134(2):279–87.

    Google Scholar 

  69. Yildiz AE, Oguz KK, Fitoz S. Suprasellar masses in children: characteristic MR imaging features. J Neuroradiol. 2016;43(4):246–59.

    PubMed  Google Scholar 

  70. Shapey J, Danesh-Meyer HV, Kaye AH. Diagnosis and management of optic nerve glioma. J Clin Neurosci. 2011;18(12):1585–91.

    CAS  PubMed  Google Scholar 

  71. Lee AG. Neuroophthalmological management of optic pathway gliomas. Neurosurg Focus. 2007;23(5):E1.

    PubMed  Google Scholar 

  72. Avery RA, Fisher MJ, Liu GT. Optic pathway gliomas. J Neuroophthalmol. 2011;31(3):269–78.

    PubMed  Google Scholar 

  73. Dasgupta B, et al. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res. 2005;65(7):2755–60.

    CAS  PubMed  Google Scholar 

  74. Gutmann DH, et al. Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas. Neuropathol Appl Neurobiol. 2000;26(4):361–7.

    CAS  PubMed  Google Scholar 

  75. Khatua S, Gutmann DH, Packer RJ. Neurofibromatosis type 1 and optic pathway glioma: molecular interplay and therapeutic insights. Pediatr Blood Cancer. 2018;65(3):e26838.

    Google Scholar 

  76. Jones DT, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68(21):8673–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  77. Jacob K, et al. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. Clin Cancer Res. 2011;17(14):4650–60.

    CAS  PubMed  Google Scholar 

  78. Maixner W. Hypothalamic hamartomas--clinical, neuropathological and surgical aspects. Childs Nerv Syst. 2006;22(8):867–73.

    PubMed  Google Scholar 

  79. Debeneix C, et al. Hypothalamic hamartoma: comparison of clinical presentation and magnetic resonance images. Horm Res. 2001;56(1–2):12–8.

    CAS  PubMed  Google Scholar 

  80. Weissenberger AA, et al. Aggression and psychiatric comorbidity in children with hypothalamic hamartomas and their unaffected siblings. J Am Acad Child Adolesc Psychiatry. 2001;40(6):696–703.

    CAS  PubMed  Google Scholar 

  81. Harrison VS, Oatman O, Kerrigan JF. Hypothalamic hamartoma with epilepsy: Review of endocrine comorbidity. Epilepsia. 2017;58(Suppl 2):50–9.

    PubMed  PubMed Central  Google Scholar 

  82. Chemaitilly W, et al. Central precocious puberty: clinical and laboratory features. Clin Endocrinol. 2001;54(3):289–94.

    CAS  Google Scholar 

  83. Pescovitz OH, et al. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy. J Pediatr. 1986;108(1):47–54.

    CAS  PubMed  Google Scholar 

  84. Judge DM, et al. Hypothalamic hamartoma: a source of luteinizing-hormone-releasing factor in precocious puberty. N Engl J Med. 1977;296(1):7–10.

    CAS  PubMed  Google Scholar 

  85. Mittal S, et al. Hypothalamic hamartomas. Part 1. Clinical, neuroimaging, and neurophysiological characteristics. Neurosurg Focus. 2013;34(6):E6.

    PubMed  Google Scholar 

  86. Jung H, et al. Association of morphological characteristics with precocious puberty and/or gelastic seizures in hypothalamic hamartoma. J Clin Endocrinol Metab. 2003;88(10):4590–5.

    CAS  PubMed  Google Scholar 

  87. Ng YT, et al. Transcallosal resection of hypothalamic hamartoma for intractable epilepsy. Epilepsia. 2006;47(7):1192–202.

    PubMed  Google Scholar 

  88. Ng YT, et al. Endoscopic resection of hypothalamic hamartomas for refractory symptomatic epilepsy. Neurology. 2008;70(17):1543–8.

    PubMed  Google Scholar 

  89. Abla AA, et al. Gamma Knife surgery for hypothalamic hamartomas and epilepsy: patient selection and outcomes. J Neurosurg. 2010;113(Suppl):207–14.

    PubMed  Google Scholar 

  90. Abla AA, et al. Orbitozygomatic resection for hypothalamic hamartoma and epilepsy: patient selection and outcome. Childs Nerv Syst. 2011;27(2):265–77.

    PubMed  Google Scholar 

  91. Drees C, et al. Seizure outcome and complications following hypothalamic hamartoma treatment in adults: endoscopic, open, and gamma knife procedures. J Neurosurg. 2012;117(2):255–61.

    PubMed  Google Scholar 

  92. Li CD, et al. Surgical treatment of hypothalamic hamartoma causing central precocious puberty: long-term follow-up. J Neurosurg Pediatr. 2013;12(2):151–4.

    PubMed  Google Scholar 

  93. Ng YT, et al. Successful resection of a hypothalamic hamartoma and a Rathke cleft cyst. Case report. J Neurosurg. 2005;102(1 Suppl):78–80.

    PubMed  Google Scholar 

  94. Graham JM Jr, et al. A cluster of pallister-hall syndrome cases, (congenital hypothalamic hamartoblastoma syndrome). Am J Med Genet Suppl. 1986;2:53–63.

    PubMed  Google Scholar 

  95. Freeman JL, et al. The endocrinology of hypothalamic hamartoma surgery for intractable epilepsy. Epileptic Disord. 2003;5(4):239–47.

    PubMed  Google Scholar 

  96. Alter CA, Bilaniuk LT. Utility of magnetic resonance imaging in the evaluation of the child with central diabetes insipidus. J Pediatr Endocrinol Metab. 2002;15(Suppl 2):681–7.

    PubMed  Google Scholar 

  97. Mootha SL, et al. Idiopathic hypothalamic diabetes insipidus, pituitary stalk thickening, and the occult intracranial germinoma in children and adolescents. J Clin Endocrinol Metab. 1997;82(5):1362–7.

    CAS  PubMed  Google Scholar 

  98. Marchand I, et al. Central diabetes insipidus as the inaugural manifestation of Langerhans cell histiocytosis: natural history and medical evaluation of 26 children and adolescents. J Clin Endocrinol Metab. 2011;96(9):E1352–60.

    CAS  PubMed  Google Scholar 

  99. Saito T, et al. Chronic hypernatremia associated with inflammation of the neurohypophysis. J Clin Endocrinol Metab. 1970;31(4):391–6.

    CAS  PubMed  Google Scholar 

  100. Robison NJ, et al. Predictors of neoplastic disease in children with isolated pituitary stalk thickening. Pediatr Blood Cancer. 2013;60(10):1630–5.

    PubMed  Google Scholar 

  101. Raybaud C, Barkovich AJ. Intracranial, orbital, and neck masses of childhood. In: Barkovich AJ, Raybaud C, editors. Pediatric neuroimaging. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2012.

    Google Scholar 

  102. Echevarria ME, Fangusaro J, Goldman S. Pediatric central nervous system germ cell tumors: a review. Oncologist. 2008;13(6):690–9.

    PubMed  Google Scholar 

  103. Phi JH, et al. The enigma of bifocal germ cell tumors in the suprasellar and pineal regions: synchronous lesions or metastasis? J Neurosurg Pediatr. 2013;11(2):107–14.

    PubMed  Google Scholar 

  104. Board PDQPTE. Childhood central nervous system germ cell tumors treatment (PDQ(R)): health professional version. In:PDQ cancer information summaries. Bethesda, MD: National Cancer Institute (US); 2002.

    Google Scholar 

  105. Goodwin TL, Sainani K, Fisher PG. Incidence patterns of central nervous system germ cell tumors: a SEER Study. J Pediatr Hematol Oncol. 2009;31(8):541–4.

    PubMed  Google Scholar 

  106. Villano JL, et al. Malignant pineal germ-cell tumors: an analysis of cases from three tumor registries. Neuro-Oncology. 2008;10(2):121–30.

    PubMed  PubMed Central  Google Scholar 

  107. Jenkin RD, Simpson WJ, Keen CW. Pineal and suprasellar germinomas. Results of radiation treatment. J Neurosurg. 1978;48(1):99–107.

    CAS  PubMed  Google Scholar 

  108. Matsutani M, et al. Primary intracranial germ cell tumors: a clinical analysis of 153 histologically verified cases. J Neurosurg. 1997;86(3):446–55.

    CAS  PubMed  Google Scholar 

  109. Jennings MT, Gelman R, Hochberg F. Intracranial germ-cell tumors: natural history and pathogenesis. J Neurosurg. 1985;63(2):155–67.

    CAS  PubMed  Google Scholar 

  110. Brandes AA, Pasetto LM, Monfardini S. The treatment of cranial germ cell tumours. Cancer Treat Rev. 2000;26(4):233–42.

    CAS  PubMed  Google Scholar 

  111. Sklar CA, et al. Hormonal and metabolic abnormalities associated with central nervous system germinoma in children and adolescents and the effect of therapy: report of 10 patients. J Clin Endocrinol Metab. 1981;52(1):9–16.

    CAS  PubMed  Google Scholar 

  112. Ono N, et al. A comparison of children with suprasellar germ cell tumors and craniopharyngiomas: final height, weight, endocrine, and visual sequelae after treatment. Surg Neurol. 1996;46(4):370–7.

    CAS  PubMed  Google Scholar 

  113. Vuillermet P, et al. Simultaneous suprasellar and pineal germ cell tumors in five late stage adolescents: endocrinological studies and prolonged follow-up. J Pediatr Endocrinol Metab. 2008;21(12):1169–78.

    CAS  PubMed  Google Scholar 

  114. Reddy AT, et al. Refining the staging evaluation of pineal region germinoma using neuroendoscopy and the presence of preoperative diabetes insipidus. Neuro-Oncology. 2004;6(2):127–33.

    PubMed  PubMed Central  Google Scholar 

  115. Ramelli GP, et al. Suprasellar germinomas in childhood and adolescence: diagnostic pitfalls. J Pediatr Endocrinol Metab. 1998;11(6):693–7.

    CAS  PubMed  Google Scholar 

  116. Fujimaki T. Central nervous system germ cell tumors: classification, clinical features, and treatment with a historical overview. J Child Neurol. 2009;24(11):1439–45.

    PubMed  Google Scholar 

  117. Ono N, et al. Suprasellar germinomas; relationship between tumour size and diabetes insipidus. Acta Neurochir. 1992;114(1–2):26–32.

    CAS  PubMed  Google Scholar 

  118. Allen J, et al. Diagnostic sensitivity of serum and lumbar CSF bHCG in newly diagnosed CNS germinoma. Pediatr Blood Cancer. 2012;59(7):1180–2.

    PubMed  PubMed Central  Google Scholar 

  119. Osorio DS, Allen JC. Management of CNS germinoma. CNS Oncol. 2015;4(4):273–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  120. Packer RJ, Cohen BH, Cooney K. Intracranial germ cell tumors. Oncologist. 2000;5(4):312–20.

    CAS  PubMed  Google Scholar 

  121. Maity A, et al. Craniospinal radiation in the treatment of biopsy-proven intracranial germinomas: twenty-five years' experience in a single center. Int J Radiat Oncol Biol Phys. 2004;58(4):1165–70.

    PubMed  Google Scholar 

  122. Kawabata Y, et al. Long term outcomes in patients with intracranial germinomas: a single institution experience of irradiation with or without chemotherapy. J Neuro-Oncol. 2008;88(2):161–7.

    Google Scholar 

  123. Sawamura Y, et al. Germ cell tumours of the central nervous system: treatment consideration based on 111 cases and their long-term clinical outcomes. Eur J Cancer. 1998;34(1):104–10.

    CAS  PubMed  Google Scholar 

  124. Robertson PL, DaRosso RC, Allen JC. Improved prognosis of intracranial non-germinoma germ cell tumors with multimodality therapy. J Neuro-Oncol. 1997;32(1):71–80.

    CAS  Google Scholar 

  125. Calaminus G, et al. AFP/beta-HCG secreting CNS germ cell tumors: long-term outcome with respect to initial symptoms and primary tumor resection. Results of the cooperative trial MAKEI 89. Neuropediatrics. 2005;36(2):71–7.

    CAS  PubMed  Google Scholar 

  126. Henter JI, Tondini C, Pritchard J. Histiocyte disorders. Crit Rev Oncol Hematol. 2004;50(2):157–74.

    PubMed  Google Scholar 

  127. Grois N, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010;156(6):873–81, 881.e1.

    PubMed  Google Scholar 

  128. Alston RD, et al. Incidence and survival of childhood Langerhans cell histiocytosis in Northwest England from 1954 to 1998. Pediatr Blood Cancer. 2007;48(5):555–60.

    CAS  PubMed  Google Scholar 

  129. Guyot-Goubin A, et al. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000–2004. Pediatr Blood Cancer. 2008;51(1):71–5.

    PubMed  Google Scholar 

  130. Salotti JA, et al. Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Arch Dis Child. 2009;94(5):376–80.

    CAS  PubMed  Google Scholar 

  131. Stalemark H, et al. Incidence of Langerhans cell histiocytosis in children: a population-based study. Pediatr Blood Cancer. 2008;51(1):76–81.

    PubMed  Google Scholar 

  132. Grois N, et al. Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer. 2006;46(2):228–33.

    CAS  PubMed  Google Scholar 

  133. Donadieu J, et al. Incidence of growth hormone deficiency in pediatric-onset Langerhans cell histiocytosis: efficacy and safety of growth hormone treatment. J Clin Endocrinol Metab. 2004;89(2):604–9.

    CAS  PubMed  Google Scholar 

  134. Nanduri VR, et al. Growth and endocrine disorders in multisystem Langerhans’ cell histiocytosis. Clin Endocrinol. 2000;53(4):509–15.

    CAS  Google Scholar 

  135. Abla O, Egeler RM, Weitzman S. Langerhans cell histiocytosis: current concepts and treatments. Cancer Treat Rev. 2010;36(4):354–9.

    CAS  PubMed  Google Scholar 

  136. Aquilina K, Boop FA. Nonneoplastic enlargement of the pituitary gland in children. J Neurosurg Pediatr. 2011;7(5):510–5.

    PubMed  Google Scholar 

  137. Kocova M, et al. Diagnostic approach in children with unusual symptoms of acquired hypothyroidism. When to look for pituitary hyperplasia? J Pediatr Endocrinol Metab. 2016;29(3):297–303.

    PubMed  Google Scholar 

  138. Satyarthee GD, Sharma BS. Repeated headache as presentation of pituitary apoplexy in the adolescent population: unusual entity with review of literature. J Neurosci Rural Pract. 2017;8(Suppl 1):S143–s146.

    PubMed  PubMed Central  Google Scholar 

  139. Chao CC, Lin CJ. Pituitary apoplexy in a teenager--case report. Pediatr Neurol. 2014;50(6):648–51.

    PubMed  Google Scholar 

  140. Spampinato MV, Castillo M. Congenital pathology of the pituitary gland and parasellar region. Top Magn Reson Imaging. 2005;16(4):269–76.

    PubMed  Google Scholar 

  141. Tominaga JY, Higano S, Takahashi S. Characteristics of Rathke’s cleft cyst in MR imaging. Magn Reson Med Sci. 2003;2(1):1–8.

    PubMed  Google Scholar 

  142. Teramoto A, et al. Incidental pituitary lesions in 1000 unselected autopsy specimens. Radiology. 1994;193(1):161–4.

    CAS  PubMed  Google Scholar 

  143. Han SJ, et al. Rathke’s cleft cysts: review of natural history and surgical outcomes. J Neuro-Oncol. 2014;117(2):197–203.

    Google Scholar 

  144. Evliyaoglu O, Evliyaoglu C, Ayva S. Rathke cleft cyst in seven-year-old girl presenting with central diabetes insipidus and review of literature. J Pediatr Endocrinol Metab. 2010;23(5):525–9.

    PubMed  Google Scholar 

  145. Al-Holou WN, et al. Prevalence and natural history of arachnoid cysts in children. J Neurosurg Pediatr. 2010;5(6):578–85.

    PubMed  Google Scholar 

  146. Rao G, et al. Expansion of arachnoid cysts in children: report of two cases and review of the literature. J Neurosurg. 2005;102(3 Suppl):314–7.

    PubMed  Google Scholar 

  147. Pradilla G, Jallo G. Arachnoid cysts: case series and review of the literature. Neurosurg Focus. 2007;22(2):E7.

    PubMed  Google Scholar 

  148. Guzel A, Trippel M, Ostertage CB. Suprasellar arachnoid cyst: a 20- year follow-up after stereotactic internal drainage: case report and review of the literature. Turk Neurosurg. 2007;17(3):211–8.

    PubMed  Google Scholar 

  149. Invergo D, Tomita T. De novo suprasellar arachnoid cyst: case report and review of the literature. Pediatr Neurosurg. 2012;48(3):199–203.

    PubMed  Google Scholar 

  150. Lee JY, et al. Long-term endocrine outcome of suprasellar arachnoid cysts. J Neurosurg Pediatr. 2017;19(6):696–702.

    PubMed  Google Scholar 

  151. Caldarelli M, et al. Intracranial midline dermoid and epidermoid cysts in children. J Neurosurg. 2004;100(5 Suppl Pediatrics):473–80.

    PubMed  Google Scholar 

  152. Amelot A, et al. Child dermoid cyst mimicking a craniopharyngioma: the benefit of MRI T2-weighted diffusion sequence. Childs Nerv Syst. 2018;34(2):359–62.

    Google Scholar 

  153. Zada G, Lopes MBS, Mukundan S, Laws E. Sellar region epidermoid and dermoid cysts. In: Zada G, Lopes M, Mukundan Jr S, Laws Jr E, editors. Atlas of sellar and parasellar lesions. Cham: Springer; 2016.

    Google Scholar 

  154. Gasparini S, et al. The journey of a floating fat: from suprasellar dermoid cyst to lateral ventricles. Neurol Sci. 2018;39(2):381–2.

    CAS  PubMed  Google Scholar 

  155. Osborn AG, Preece MT. Intracranial cysts: radiologic-pathologic correlation and imaging approach. Radiology. 2006;239(3):650–64.

    PubMed  Google Scholar 

  156. Kalra AA, Riel-Romero RM, Gonzalez-Toledo E. Lymphocytic hypophysitis in children: a novel presentation and literature review. J Child Neurol. 2011;26(1):87–94.

    PubMed  Google Scholar 

  157. Gellner V, et al. Lymphocytic hypophysitis in the pediatric population. Childs Nerv Syst. 2008;24(7):785–92.

    PubMed  Google Scholar 

  158. Molitch ME, Gillam MP. Lymphocytic hypophysitis. Horm Res. 2007;68(Suppl 5):145–50.

    PubMed  Google Scholar 

  159. Caturegli P. Autoimmune hypophysitis: an underestimated disease in search of its autoantigen(s). J Clin Endocrinol Metab. 2007;92(6):2038–40.

    CAS  PubMed  Google Scholar 

  160. Rivera JA. Lymphocytic hypophysitis: disease spectrum and approach to diagnosis and therapy. Pituitary. 2006;9(1):35–45.

    PubMed  Google Scholar 

  161. Sato N, Sze G, Endo K. Hypophysitis: endocrinologic and dynamic MR findings. AJNR Am J Neuroradiol. 1998;19(3):439–44.

    CAS  PubMed  Google Scholar 

  162. Maghnie M, et al. Evolution of childhood central diabetes insipidus into panhypopituitarism with a large hypothalamic mass: is ‘lymphocytic infundibuloneurohypophysitis’ in children a different entity? Eur J Endocrinol. 1998;139(6):635–40.

    CAS  PubMed  Google Scholar 

  163. Corsello SM, et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98(4):1361–75.

    CAS  PubMed  Google Scholar 

  164. Yang JC, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825–30.

    CAS  PubMed  PubMed Central  Google Scholar 

  165. Torino F, et al. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist. 2012;17(4):525–35.

    PubMed  PubMed Central  Google Scholar 

  166. Torino F, et al. Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol. 2013;169(6):R153–64.

    CAS  PubMed  Google Scholar 

  167. Blansfield JA, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005;28(6):593–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  168. Chodakiewitz Y, et al. Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis. Clin Neurol Neurosurg. 2014;125:125–30.

    PubMed  Google Scholar 

  169. Ryder M, et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21(2):371–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  170. Downey SG, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13(22 Pt 1):6681–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  171. Roessmann U, Kaufman B, Friede RL. Metastatic lesions in the sella turcica and pituitary gland. Cancer. 1970;25(2):478–80.

    CAS  PubMed  Google Scholar 

  172. Nagashima H, et al. Medulloblastoma with suprasellar solitary massive metastasis: case report. Neurol Neurochir Pol. 2016;50(3):211–4.

    PubMed  Google Scholar 

  173. Muller HL, et al. Post-operative hypothalamic lesions and obesity in childhood craniopharyngioma: results of the multinational prospective trial KRANIOPHARYNGEOM 2000 after 3-year follow-up. Eur J Endocrinol. 2011;165(1):17–24.

    PubMed  Google Scholar 

  174. Muller HL, et al. Functional capacity, obesity and hypothalamic involvement: cross-sectional study on 212 patients with childhood craniopharyngioma. Klin Padiatr. 2003;215(6):310–4.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Endocrinology, NYU Langone Medical Center, New York, NY, USA

    Shilpa Mehta

  2. Division of Radiology, NYU Langone Medical Center, New York, NY, USA

    Benjamin Cohen

  3. Division of Pediatric Endocrinology and Diabetes, New York University – Langone Medical Center, Hassenfeld Children’s Hospital, New York, NY, USA

    Brenda Kohn

Authors
  1. Shilpa Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benjamin Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brenda Kohn
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Pediatric Endocrinology, New York University, New York, NY, USA

    Brenda Kohn

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Mehta, S., Cohen, B., Kohn, B. (2019). Nonpituitary Sellar Masses and Infiltrative Disorders. In: Kohn, B. (eds) Pituitary Disorders of Childhood. Contemporary Endocrinology. Humana Press, Cham. https://doi.org/10.1007/978-3-030-11339-1_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-11339-1_10

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-030-11338-4

  • Online ISBN: 978-3-030-11339-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation